Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 0.46 |
| ▸ | HRH1 known ✓ | P35367 | 2/20 | 0.43 |
| ▸ | SLC6A4 known ✓ | P31645 | 3/20 | 0.41 |
| ▸ | SLC6A3 known ✓ | Q01959 | 3/20 | 0.41 |
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.41 |
| ▸ | DPP4 known ✓ | P27487 | 2/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15156585 | 0.98 | TAAR1 (0.48) | TAAR1HTR2AHRH1SLC6A4SLC6A3 | |
| SCHEMBL10961816 | 0.79 | TAAR1 (0.48) | TAAR1HTR2AHRH1SLC6A4SLC6A3 | |
| SCHEMBL7525369 | 0.76 | TAAR1 (0.50) | TAAR1HTR2AHRH1SLC6A4SLC6A3 | |
| SCHEMBL29998636 | 0.76 | TAAR1 (0.45) | TAAR1HTR2AHRH1SLC6A4SLC6A3 | |
| SCHEMBL10380299 | 0.76 | AOC3 (0.46) | TAAR1HTR2AHRH1SLC6A4SLC6A3 | |
| SCHEMBL2302238 | 0.72 | DPP4 (0.48) | TAAR1HTR2AHRH1DPP4F2 | |
| Hydrochloric Acid SCHEMBL17645582 | 0.70 | SLC6A2 (0.41) | TAAR1HTR2ASLC6A4SLC6A3SLC6A2 | |
| Water SCHEMBL28973054 | 0.70 | TAAR1 (0.48) | TAAR1HTR2AHRH1CHRNB2CHRNA4 | |
| SCHEMBL352841 | 0.69 | TAAR1 (0.46) | TAAR1HTR2ASLC6A4SLC6A3SLC6A2 | |
| Hydrochloric Acid SCHEMBL8550503 | 0.67 | HTR2A (0.94) | TAAR1HTR2AHRH1SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3310783-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF HEARING LOSS | Zuo, Jian (US) | 2018-04-25 | — | — | EP | disclosed |
| EP-2152752-B1 | ANTIBODY DIRECTED TO G PROTEIN COUPLED RECEPTORS (GPCR) | HOFFMANN LA ROCHE (CH) | 2017-11-08 | — | — | EP | disclosed |
| WO-2016205806-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF HEARING LOSS | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2016-12-22 | — | — | WO | disclosed |
| CN-102105133-B | Controlled release otic structure modulating and innate immune system modulating compositions and methods of treating otic disorders | OTONOMY INC | 2015-06-17 | — | — | CN | disclosed |
| CN-101687927-B | Antibody directed to G protein coupled receptors (GPCR) | HOFFMANN LA ROCHE | 2013-10-30 | — | — | CN | disclosed |
| US-8354102-B2 | Antibodies directed to mGluR7 | HOFFMANN-LA ROCHE INC. (US) | 2013-01-15 | — | — | US | disclosed |
| EP-2490722-A2 | MODULATION OF GEL TEMPERATURE OF POLOXAMER-CONTAINING FORMULATIONS | Otonomy, Inc. (US) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011049958-A2 | MODULATION OF GEL TEMPERATURE OF POLOXAMER-CONTAINING FORMULATIONS | OTONOMY, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
| US-20100303802-A1 | ANTIBODY DIRECTED TO G PROTEIN COUPLED RECEPTORS (GPCR) | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-02 | — | — | US | disclosed |
| CN-101687927-A | antibody directed to g protein coupled receptors (gpcr) | HOFFMANN LA ROCHE | 2010-03-31 | — | — | CN | disclosed |
| EP-2152752-A2 | ANTIBODY DIRECTED TO G PROTEIN COUPLED RECEPTORS (GPCR) | F. Hoffmann-Roche AG (CH) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008138536-A2 | ANTIBODY DIRECTED TO G PROTEIN COUPLED RECEPTORS (GPCR) | F. HOFFMANN-LA ROCHE AG (CH) | 2008-11-20 | — | — | WO | disclosed |